| BNT162b2 vaccine booster and mortality due to Covid-19 R Arbel, A Hammerman, R Sergienko, M Friger, A Peretz, D Netzer, ... New England Journal of Medicine 385 (26), 2413-2420, 2021 | 352 | 2021 |
| Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge R Arbel, Y Wolff Sagy, M Hoshen, E Battat, G Lavie, R Sergienko, M Friger, ... New England Journal of Medicine 387 (9), 790-798, 2022 | 265 | 2022 |
| Method and system for cardiovascular system diagnosis R Arbel, Y Tal, M Ortenberg US Patent App. 11/489,721, 2007 | 138 | 2007 |
| Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years R Arbel, R Sergienko, M Friger, A Peretz, T Beckenstein, S Yaron, ... Nature medicine 28 (7), 1486-1490, 2022 | 123 | 2022 |
| Effectiveness of the BNT162b2 vaccine after recovery from Covid-19 A Hammerman, R Sergienko, M Friger, T Beckenstein, A Peretz, D Netzer, ... New England Journal of Medicine 386 (13), 1221-1229, 2022 | 115 | 2022 |
| Real-world effectiveness of a single dose of mpox vaccine in males Y Wolff Sagy, R Zucker, A Hammerman, H Markovits, NG Arieh, ... Nature Medicine 29 (3), 748-752, 2023 | 100 | 2023 |
| Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study R Arbel, A Peretz, R Sergienko, M Friger, T Beckenstein, H Duskin-Bitan, ... The Lancet Infectious Diseases 23 (8), 914-921, 2023 | 83 | 2023 |
| Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation R Arbel, R Sergienko, A Hammerman, S Greenberg-Dotan, E Batat, ... The American Journal of Medicine 132 (7), 847-855. e3, 2019 | 83 | 2019 |
| Method and system for cardiovascular system diagnosis R Arbel, Y Tal, M Ortenberg US Patent 7,771,364, 2010 | 35 | 2010 |
| Method and system for cardiovascular system diagnosis R Arbel, Y Tal, M Ortenberg US Patent App. 11/892,256, 2008 | 31 | 2008 |
| Effectiveness of a single-dose Modified Vaccinia Ankara in Human Monkeypox: an observational study R Arbel, YW Sagy, R Zucker, NG Arieh, H Markovits, W Abu-Ahmad, ... Research Square, 2022 | 19 | 2022 |
| PCSK9 inhibitors may improve cardiovascular outcomes—Can we afford them? R Arbel, A Hammerman, N Triki, D Greenberg International Journal of Cardiology 220, 242-245, 2016 | 16 | 2016 |
| Prediction of short-term atrial fibrillation risk using primary care electronic health records R Nadarajah, J Wu, D Hogg, K Raveendra, YM Nakao, K Nakao, R Arbel, ... Heart 109 (14), 1072-1079, 2023 | 14 | 2023 |
| Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis J Azuri, A Hammerman, E Aboalhasan, B Sluckis, R Arbel Diabetes, Obesity and Metabolism 25 (4), 961-964, 2023 | 14 | 2023 |
| Usefulness of ezetimibe versus evolocumab as add-on therapy for secondary prevention of cardiovascular events in patients with type 2 diabetes mellitus R Arbel, A Hammerman, J Azuri The American Journal of Cardiology 123 (8), 1273-1276, 2019 | 13 | 2019 |
| Vaccinations versus lockdowns to prevent COVID-19 mortality R Arbel, J Pliskin Vaccines 10 (8), 1347, 2022 | 12 | 2022 |
| Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis R Arbel, E Aboalhasan, A Hammerman, J Azuri European Journal of Preventive Cardiology 28 (15), 1665-1669, 2021 | 12 | 2021 |
| Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study D Yamin, M Yechezkel, R Arbel, T Beckenstein, R Sergienko, ... The Lancet Infectious Diseases 23 (10), 1130-1142, 2023 | 11 | 2023 |
| How many lives do COVID vaccines save? Evidence from Israel R Arbel, CM Moore, R Sergienko, J Pliskin American Journal of Infection Control 50 (3), 258-261, 2022 | 11 | 2022 |
| Rethinking cost-effectiveness in the era of zero healthcare spending growth R Arbel, D Greenberg International journal for equity in health 15, 1-7, 2016 | 11 | 2016 |
Ariel HammermanHealth Technology Assessment Director, Medison Pharmaכתובת אימייל מאומתת בדומיין medisonpharma.com
